Elotuzumab for the treatment of multiple myeloma

被引：0
|
作者：
Yucai Wang
Larysa Sanchez
David S. Siegel
Michael L. Wang
机构：
[1] Rutgers New Jersey Medical School,Department of Medicine
[2] Hackensack University Medical Center,Division of Multiple Myeloma, John Theurer Cancer Center
[3] The University of Texas M. D. Anderson Cancer Center,Department of Lymphoma/Myeloma, Division of Cancer Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Natural Killer Cell; Multiple Myeloma; Thalidomide; Bortezomib; Maximum Tolerate Dose;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.
引用
收藏
相关论文
共 50 条
  • [1] Elotuzumab for the treatment of multiple myeloma
    Wang, Yucai
    Sanchez, Larysa
    Siegel, David S.
    Wang, Michael L.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] Elotuzumab for the treatment of multiple myeloma
    Moreau, Philippe
    Touzeau, Cyrille
    FUTURE ONCOLOGY, 2014, 10 (06) : 949 - 956
  • [3] Elotuzumab in multiple myeloma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (12): : E675 - E675
  • [4] Elotuzumab in the treatment of relapsed and refractory multiple myeloma
    Grosicki, Sebastian
    Bednarczyk, Martyna
    Barchnicka, Agnieszka
    Grosicka, Olga
    FUTURE ONCOLOGY, 2021, 17 (13) : 1581 - 1591
  • [5] Efficacy and safety of elotuzumab for the treatment of multiple myeloma
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (02) : 237 - 245
  • [6] Elotuzumab in multiple myeloma
    Bruzzese, Antonella
    Martino, Enrica Antonia
    Vigna, Ernesto
    Iaccino, Enrico
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Filippelli, Gianfranco
    Neri, Antonino
    Morabito, Fortunato
    Gentile, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (01) : 7 - 10
  • [7] The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma
    Comeau, Jill M.
    Kelly, Katherine
    Jean, Gary W.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (02) : 55 - 66
  • [8] Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
    Weisel, Katja
    ONCOTARGETS AND THERAPY, 2016, 9 : 6037 - 6048
  • [9] Treatment of multiple Myeloma with Elotuzumab plus Pomalidomide and Dexamethasone
    Rasche, L.
    Einsele, H.
    Nitschmann, S.
    INTERNIST, 2019, 60 (06): : 658 - 660
  • [10] Profile of elotuzumab and its potential in the treatment of multiple myeloma
    Liu, Yi-Chang
    Szmania, Susann
    van Rhee, Frits
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 15 - 27
12345